与初始药物坚持与抑郁症第一线治疗相关的因素
Sourab Ganna1, Jieni Li1, Rajender R Aparasu1
1Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, TX, USA.
Journal of affective disorders
|August 3, 2025
概括
大多数重度抑郁症患者表现出良好的初始抗抑郁药坚持,但特定的药物和患者因素影响成功. 有针对性的干预措施可以改善抗抑郁药物药物坚持.
科学领域:
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
- 医疗保健服务研究 医疗服务研究
背景情况:
- 在重大抑郁症 (MDD) 中,对抗抑郁药物的初始药物坚持 (IMA) 是至关重要的,但研究不足.
- 了解影响最佳IMA的因素对于急性治疗阶段至关重要.
研究的目的:
- 在开始抗抑郁药物治疗的大型抑郁症 (MDD) 患者中调查与最佳初始药物坚持 (IMA) 相关的因素.
- 为了确定特定的抗抑郁药物和患者特征与更好的坚持相关.
主要方法:
- 使用Merative MarketScan数据 (2017-2019) 进行的回顾性队列研究.
- 包括患有MDD的成年人 (≥18岁) 开始选择性血清素再吸收抑制剂或血清素-上腺素再吸收抑制剂.
- 最佳IMA定义为前三个月内覆盖日数 (PDC) ≥80%的比例;使用多变量后勤回归.
主要成果:
- 在397976名MDD患者中,有60.71%的患者实现了最佳的IMA.
- 最佳IMA的更高几率与埃斯基塔洛普拉姆,弗卢克塞丁,文拉法辛和莱沃米利纳西普兰有关.
- 较低的几率与帕罗克塞丁和德斯文拉法辛有关;患者人口统计学和并发症也影响了坚持.
结论:
- 大约61%的MDD患者实现了最佳的初始抗抑郁药坚持.
- 在不同的抗抑郁药物和患者个人资料中,IMA存在显著差异.
- 这些发现强调了IMA的重要性,以及需要有针对性的干预措施来提高MDD治疗的坚持.
更多相关视频
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
353
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
353
Drug Therapy
100
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
100
Factors Affecting Drug Response: Overview
2.4K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.4K
Antidepressant Drugs: Overview
757
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
757
Depressive Disorders: Etiology
169
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
169
Factors Affecting Protein-Drug Binding: Patient-Related Factors
114
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
114


